All News

Found 9,891 articles

• Celyad Oncology reports third quarter 2023 financial results and recent business highlights

  11/9/2023

  Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, reports its financial results for the third quarter of 2023 and provides an update on recent business developments.

• Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

  11/9/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.

• Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

  11/9/2023

  Vor Bio, a clinical-stage cell and genome engineering company, presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia.

• GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for “Circular RNA Therapeutics”

  11/9/2023

  GenScript ProBio and NuclixBio announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.

• Vyriad Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting

  11/9/2023

  Vyriad, Inc. announced that its abstract, In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector, has been selected for an oral presentation at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, California.

• Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

  11/9/2023

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, reported financial results for the third quarter ended September 30, 2023.

• Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

  11/9/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.  

• Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

  11/9/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.

• Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

  11/9/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

• BioLife Solutions Reports Third Quarter 2023 Financial Results

  11/9/2023

  BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced financial results for the third quarter and nine months of 2023.

• Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

  11/9/2023

  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.

• 

  Opinion: Cell Therapy Cancer Treatments Are Coming. Now to Make Them More Accessible.

  11/8/2023

  Cell and gene therapy represents the most promising breakthrough in cancer treatment for decades, but it comes with a hefty price tag. Here’s how to drive costs down.

• Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

  11/8/2023

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).

• Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program

  11/8/2023

  Gracell Biotechnologies Inc. announced that Gracell’s FasTCAR-T GC012F was selected as the winner of BioTech Breakthrough’s Overall Immunology Solution of the Year award.

• ImmPACT Bio Recognized in BioSpace's 2024 Best Places to Work

  11/8/2023

  ImmPACT Bio USA , Inc. today announced it has been named on the BioSpace 2024 Best Places to Work small employer list.

• CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

  11/8/2023

  CASI Pharmaceuticals Inc. is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas).

• Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

  11/8/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, reported financial results and business highlights for the third quarter 2023.

• Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

  11/8/2023

  Fate Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2023.

• Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

  11/8/2023

  Artiva Biotherapeutics, Inc. today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry.

• ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update

  11/8/2023

  ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2023, and provide a corporate strategic update on Thursday, November 13, 2023, after the close of trading.